Tada,

I actually wrote a post about this a few weeks ago that nobody responded to :)

FWIW, if you have a safe drug with efficacy in dementia +/- CKD, you have the potential for a $1B market cap when entering Phase 3.

The obvious issue would be acquiring the financing and the dilution required.

The stock would clearly drop if the current study does not meet the top line but sellers would be wise to consider the secondary endpoints.

It might be like a mining company drilling for copper and finding gold.

bfw